AMICUS THERAPEUTICS EUROPE LIMITED

Amicus Therapeutics Europe Limited is a biotechnology organisation at the forefront of developing advanced therapies for a range of devastating rare diseases. Drawing on innovative technology platforms, the company focuses on human genetic disorders, with a particular emphasis on rare metabolic conditions, and works closely with patients, families and the wider rare-disease community to ensure safety and transparent communication.

The firm's pipeline spans several promising programmes, including the PROPEL study, and it provides dedicated resources and information for each therapeutic area. Amicus also highlights the personal stories of individuals living with rare disease, underscoring its commitment to patient-centred research and support. In addition to its scientific endeavours, the company fosters a collaborative workplace, recognised as a great place to work, and actively recruits talent across multiple locations to further its mission of changing lives.